The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound

Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

[search][options]

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

Roger Bullock

Kingshill Research Centre

Swindon

[email]@kingshill-research.org

Name/email consistency: high

[Claim this account]

Affiliations

Kingshill Research Centre, Swindon, UK. 2006 - 2007
Kingshill Research Centre, Victoria Hospital, Okus Road, Swindon SN1 4HZ, UK. 2002 - 2005
Department of Old Age Psychiatry and Kingshill Research Centre, Avon and Wiltshire Mental Health Trust, Victoria Hospital, Swindon SNI 4HZ, UK. 2002 - 2004

References

Executive dyscontrol in dementia, with emphasis on subcortical pathology and the role of butyrylcholinesterase. Bullock, R., Lane, R. Curr. Alzheimer. Res (2007) [Pubmed]
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease. Bullock, R., Bergman, H., Touchon, J., Gambina, G., He, Y., Nagel, J., Lane, R. Curr. Med. Res. Opin (2006) [Pubmed]
SGS-742 Novartis. Bullock, R. Curr. Opin. Investig. Drugs (2005) [Pubmed]
Treatment of behavioural and psychiatric symptoms in dementia: implications of recent safety warnings. Bullock, R. Curr. Med. Res. Opin (2005) [Pubmed]
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years. Bullock, R., Dengiz, A. Int. J. Clin. Pract. (2005) [Pubmed]
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Bullock, R., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., Lane, R. Curr. Med. Res. Opin (2005) [Pubmed]
Management of patients with Alzheimer's disease plus cerebrovascular disease: 12-month treatment with galantamine. Bullock, R., Erkinjuntti, T., Lilienfeld, S. Dement. Geriatr. Cogn. Disord (2004) [Pubmed]
Cholinesterase inhibitors and vascular dementia: another string to their bow?. Bullock, R. CNS. Drugs (2004) [Pubmed]
Future directions in the treatment of Alzheimer's disease. Bullock, R. Expert. Opin. Investig. Drugs (2004) [Pubmed]
The needs of the caregiver in the long-term treatment of Alzheimer disease. Bullock, R. Alzheimer. Dis. Assoc. Disord (2004) [Pubmed]
Galantamine: use in Alzheimer's disease and related disorders. Bullock, R. Expert. Rev. Neurother (2004) [Pubmed]
Realistic expectations: the management of severe Alzheimer disease. Bullock, R., Hammond, G. Alzheimer. Dis. Assoc. Disord (2003) [Pubmed]
New drugs for Alzheimer's disease and other dementias. Bullock, R. Br. J. Psychiatry (2002) [Pubmed]
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?. Bullock, R., Connolly, C. Int. J. Geriatr. Psychiatry (2002) [Pubmed]
Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Bullock, R., Cameron, A. Curr. Med. Res. Opin (2002) [Pubmed]